- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05169567
Abemaciclib (LY2835219) plus fulvestrant par rapport au placebo plus fulvestrant dans le cancer du sein déjà traité (postMONARCH)
postMONARCH : Une étude randomisée, en double aveugle, contrôlée par placebo, de phase 3 visant à comparer l'efficacité de l'abémaciclib plus fulvestrant à celle d'un placebo plus fulvestrant chez des participantes atteintes d'un cancer du sein HR+, HER2-, avancé ou métastatique après progression sur un inhibiteur CDK4 et 6 et endocrinien Thérapie
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Accès étendu
Contacts et emplacements
Lieux d'étude
-
-
-
San Juan, Argentine, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentine, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentine, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentine, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentine, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentine, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, Belgique, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgique, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, Belgique, 3500
- Jessa Ziekenhuis
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corée du Sud, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Corée du Sud, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Corée du Sud, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Corée du Sud, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Danemark, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Danemark, 7400
- Regionshospitalet Gødstrup
-
-
-
-
-
Badajoz, Espagne, 06006
- Hospital Infanta Cristina
-
Madrid, Espagne, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, Espagne, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Espagne, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Espagne, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Espagne, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Espagne, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, Espagne, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, Espagne, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, Espagne, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], Espagne, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Espagne, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, France, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, France, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, France, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, France, 85000
- CHD Vendee
-
-
-
-
-
Thessaloniki, Grèce, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Grèce, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Grèce, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Grèce, 711 10
- University General Hospital of Heraklion
-
-
-
-
-
Budapest, Hongrie, 1122
- Országos Onkológiai Intézet
-
Budapest, Hongrie, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Hongrie, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Hongrie, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Central District
-
Kfar Saba, Central District, Israël, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israël
- Rabin Medical Center
-
Ramat Gan, Central District, Israël, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israël, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israël, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israël, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italie, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italie, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italie, 20132
- Ospedale San Raffaele
-
Viterbo, Italie, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italie, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italie, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italie, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexique, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, Mexique, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, Mexique, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexique, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, Mexique, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Pologne, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Pologne, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Suède, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Suède, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Kaohsiung City, Taïwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taïwan, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taïwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taïwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taïwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taïwan, 71004
- Chi Mei Medical Center
-
-
-
-
-
Hradec Králové, Tchéquie, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Tchéquie, 53203
- Multiscan
-
-
-
-
-
Adana, Turquie (Türkiye), 01370
- Adana City Hospital
-
Ankara, Turquie (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Turquie (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Turquie (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Turquie (Türkiye), 22030
- Trakya University
-
Istanbul, Turquie (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Turquie (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Turquie (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Turquie (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, États-Unis, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, États-Unis, 92835
- Providence Medical Foundation
-
Los Alamitos, California, États-Unis, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, États-Unis, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, États-Unis, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, États-Unis, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, États-Unis, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, États-Unis, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, États-Unis, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, États-Unis, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, États-Unis, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, États-Unis, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, États-Unis, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, États-Unis, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, États-Unis, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, États-Unis, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, États-Unis, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, États-Unis, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, États-Unis, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, États-Unis, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, États-Unis, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, États-Unis, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, États-Unis, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, États-Unis, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, États-Unis, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, États-Unis, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, États-Unis, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, États-Unis, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, États-Unis, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, États-Unis, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, États-Unis, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, États-Unis, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, États-Unis, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, États-Unis, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, États-Unis, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, États-Unis, 76022
- Texas Oncology - Bedford
-
Denton, Texas, États-Unis, 76201
- Texas Oncology - Denton
-
El Paso, Texas, États-Unis, 79902
- Texas Oncology, P.A.
-
Houston, Texas, États-Unis, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, États-Unis, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, États-Unis, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, États-Unis, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, États-Unis, 75093
- Texas Oncology-Plano West
-
Plano, Texas, États-Unis, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, États-Unis, 78229
- Mays Cancer Center
-
The Woodlands, Texas, États-Unis, 77380
- US Oncology
-
Tyler, Texas, États-Unis, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, États-Unis, 84107
- Intermountain Medical Center
-
St. George, Utah, États-Unis, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, États-Unis, 22601
- Shenandoah Oncology, P.C.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Comparateur actif: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival (PFS)
Délai: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Délai: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Délai: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications et liens utiles
Publications générales
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Processus néoplasiques
- Maladies de la peau
- Maladies du sein
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Tumeurs mammaires
- Métastase néoplasmique
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Composés polycycliques
- Stéroïdes
- Composés à anneau fusionné
- Estradiol
- Estènes
- Origases
- Congénères de l'estradiol
- Hormones stéroïdes gonadiques
- Hormones gonadiques
- Fulvestrant
- abemaciclib
Autres numéros d'identification d'étude
- 18238
- I3Y-MC-JPEF (Autre identifiant: Eli Lilly and Company)
- 2021-002301-10 (Numéro EudraCT)
- 2023-506771-10-00 (Autre identifiant: EU Trial Number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Délai de partage IPD
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Critères d'accès au partage IPD
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .